Brooks Laboratories Limited has incorporated a wholly owned subsidiary named Abridge Speciality Limited on July 2, 2026, to expand its business operations in the pharmaceutical sector. The Certificate of Incorporation was issued by the Ministry of Corporate Affairs on the same day. This strategic move aims to broaden the company's corporate structure and enhance its manufacturing and marketing capabilities.

Abridge Speciality Limited has been established with an authorised share capital of ₹1,00,000. As a newly incorporated entity, it has not yet commenced business operations, making details regarding turnover and net worth not applicable. The subsidiary is classified as a related party transaction, with Brooks Laboratories Limited acting as the promoter holding 100% of the share capital.

The initial share capital was subscribed at face value at the time of incorporation. No specific governmental or regulatory approvals were required for this establishment. The company has disclosed that no further indicative time period is needed for completion as the entity is already fully incorporated.

Key Details of Abridge Speciality Limited

The information regarding the incorporation was submitted to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was signed by Krutika Rane, Company Secretary and Compliance Officer for Brooks Laboratories .

Brooks Laboratories Ltd approved the sale of 51,220 equity shares in Brooks Steriscience Limited to Steriscience Specialties Private Limited for a cash consideration of ₹20,760 per share, aggregating to approximately ₹106.33 crore. The transaction, approved by the Board on June 19, 2026, represents a partial monetization of the company's investment and is subject to completion of customary documentation and applicable regulatory requirements. Following the sale, Brooks Laboratories will retain a 32.67% stake in Brooks Steriscience, holding 1,02,440 equity shares, down from a previous holding of 49.00%.

The disposal of 16.33% of the share capital does not constitute a complete divestment, allowing the company to maintain a significant interest in the entity. The deal is not classified as a related party transaction, and the promoter or promoter group has no interest in the entity being disposed of. The transaction details were disclosed in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Proceeds from the sale will be deployed towards the company's growth strategy. The capital will be utilized for the expansion of operations, capacity enhancement, funding of business opportunities, and general corporate purposes. The transaction is expected to be completed in accordance with applicable laws and regulations.

Transaction Details